Severity of Sarcopenia in Parkinson's Disease

This study aimed to determine the prevalence of sarcopenia and dynapenia in Parkinson's disease patients, classified into early-stage (<2.5) and moderate-stage (≥2.5) according to the Modified Hoehn and Yahr scale, and healthy controls using the ICF-based ISarcoPRM algorithm, and to examine the differences in regional muscle morphology, muscle strength, and physical performance between groups.This study was conducted as a cross-sectional research. The study included 43 Parkinson's disease patients aged 50-75 years, classified as stages 1-3 according to the Modified Hoehn-Yahr Scale, and 22 healthy individuals with similar demographic characteristics. Parkinson's disease patients were divided into two subgroups according to the Modified Hoehn-Yahr Scale: early stage (<2.5) and intermediate stage (≥2.5). Demographic information of all participants was recorded, and clinical evaluations were performed. Parkinson's disease staging was assessed using the Modified Hoehn-Yahr Scale. Muscle mass was assessed using ultrasonography to measure anterior femoral muscle thickness. Muscle strength was measured by handgrip strength, and physical performance was assessed using a five-count sit-up test.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson Disease Atrophy Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Muscular Atrophy Nervous System Diseases Neurodegenerative Diseases Neurologic Manifestations Neuromuscular Manifestations Parkinsonian Disorders Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Sarcopenia Signs and Symptoms Synucleinopathies

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Atılım University

Ankara, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Score between 24 and 30 on the Mini Mental State Examination
Be diagnosed with Parkinson's Disease by a neurologist
Stage 1-3 on the Modified Hoehn and Yahr Scale

Exclusion criteria

Inability to communicate verbally
Elderly people with severe visual impairment, neurological disorders in addition to Parkinson's and/or congestive heart failure
Older adults in whom exercise is not recommended

Treatment and study plan

Primary outcomes

Ultrasonographic Measurement

Time frame: Baseline

For sarcopenia evaluation, anterior thigh muscle thickness will be measured by ultrasonography.
Five Times Sit to Stand Test

Time frame: Baseline

This test measures the time it takes for an individual to stand up and sit down 5 times as quickly as possible, starting from a sitting position without using their arms.
Hand Grip Strength

Time frame: Baseline

In this test, the individual will sit on a chair with their feet flat on the floor. The Jamar Hand Dynamometer will be used for measurement. They will be asked to squeeze the dynamometer firmly with their shoulders adducted and in neutral rotation, their elbows in 90-degree flexion, their forearms neutral and supported, and their wrists neutral. 3 repetitions will be done and the average will be taken.

Sponsors and collaborators

Lead sponsor

Ankara University

Other

Registry information

Official study title

Investigation of Sarcopenia Severity in Patients With Parkinson's Disease

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2025
First posted: Jun 11, 2025
Registry last updated: Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed